

First Quarter

# 2024 Financial Results



Delivering on our purpose of using the power of leading-edge science to save and improve lives around the world



Drove strong growth in oncology and vaccines



Achieved regulatory and clinical milestones



Expanded and diversified pipeline with promising business development



“We have begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing the impact of our broad commercial portfolio for the benefit of patients. We drove strong growth across key therapeutic areas, executed strategic business development, and in the U.S., we are now launching WINREVAIR, a significant new product in the cardiometabolic space for adults with pulmonary arterial hypertension, a progressive and debilitating disease. We have important opportunities ahead of us across all areas of our business, and we are highly focused on realizing them.”

Rob Davis  
Chairman and Chief Executive Officer, MSD

WORLDWIDE SALES

GAAP EPS<sup>1</sup>

NON-GAAP EPS<sup>1,2</sup>

Q1 performance reflects continued growth

\$15.8B

\$1.87

\$2.07

Updated ranges for 2024 financial outlook

\$63.1B  
to  
\$64.3B

\$8.53  
to  
\$8.65

Sales

**KEYTRUDA**  
(pembrolizumab) injection 100mg

**GARDASIL**  
(Human Papillomavirus Quadrivalent  
(Types 6, 11, 16, and 18) Vaccine, Recombinant)

**GARDASIL.9**  
Human Papillomavirus  
9-valent Vaccine, Recombinant

**MSD**  
Animal Health

\$6.9B

20% Growth

\$2.2B

14% Growth

\$1.5B

1% Growth



Q1  
2024  
Financial Results

<sup>1</sup>GAAP and non-GAAP EPS include a charge of \$0.26 per share for acquisition of Harpoon Therapeutics, Inc.

<sup>2</sup>A reconciliation of GAAP to non-GAAP EPS can be found in the company's earnings release.